Ivabradine approved by NICE for heart failure

The National Institute for Health and Clinical Excellence has accepted ivabradine (Procoralan) for use in certain patients with chronic heart failure.

Chronic heart failure affects about 900,000 people in the UK and is often caused by coronary artery disease, for example following an acute MI  | SCIENCE PHOTO LIBRARY
Chronic heart failure affects about 900,000 people in the UK and is often caused by coronary artery disease, for example following an acute MI | SCIENCE PHOTO LIBRARY

The sinus node If inhibitor is recommended as an option for prescribing on the NHS to patients:

  • with NHYA class II–IV stable chronic heart failure with systolic dysfunction and
  • who are in sinus rhythm with a heart rate ≥75 bpm and
  • who are also receiving standard therapy, including a beta-blocker, an ACE inhibitor and an aldosterone antagonist, or when a beta-blocker is contraindicated or not tolerated, and
  • who have a reduced left ventricular ejection fraction (LVEF) ≤35%.

May be managed in primary care following initiation

Patients should only be prescribed ivabradine following 4 weeks of optimised standard therapy and under the supervision of a heart failure specialist with access to a multidisciplinary team. Subsequent dose titration and monitoring can be managed either by the same specialist or by a GP with a special interest in heart failure or a heart failure specialist nurse.

Dose adjusted according to response and heart rate

Patients should be started on 5mg twice daily with morning and evening meals. The dose is then adjusted according to response and heart rate, within range 2.5–7.5mg twice daily.

NICE guidance on ivabradine in heart failure

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more